Isorhamnetin protects against bleomycin-induced pulmonary fibrosis by inhibiting endoplasmic reticulum stress and epithelial-mesenchymal transition

Zheng,Qing; Tong,Ming; Ou,Baiqing; Liu,Cuizhong; Hu,Changping; Yang,Yu

doi:10.3892/ijmm.2018.3965

Isorhamnetin protects against bleomycin-induced pulmonary fibrosis by inhibiting endoplasmic reticulum stress and epithelial-mesenchymal transition

Authors:
- Qing Zheng
- Ming Tong
- Baiqing Ou
- Cuizhong Liu
- Changping Hu
- Yu Yang
View Affiliations

Affiliations: Department of Geriatrics, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China, Department of Infectious Diseases, Hunan Provincial People's Hospital, Hunan Normal University, Changsha, Hunan 410005, P.R. China, Department of Geriatrics, Hunan Provincial People's Hospital, Hunan Normal University, Changsha, Hunan 410005, P.R. China, Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410078, P.R. China
Published online on: October 30, 2018 https://doi.org/10.3892/ijmm.2018.3965
Pages: 117-126
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to determine whether isorhamnetin (Isor), a natural antioxidant polyphenol, has antifibrotic effects in a murine model of bleomycin‑induced pulmonary fibrosis. A C57 mouse model of pulmonary fibrosis was established by intraperitoneal injection of a single dose of bleomycin (3.5 U/kg), and then Isor (10 and 30 mg/kg) was administered intragastrically. The level of fibrosis was assessed by hematoxylin and eosin and Sirius red staining. α‑smooth muscle actin and type I collagen levels in lung tissues were determined by western blotting and immunohistochemistry (IHC). Epithelial‑mesenchymal transition (EMT), endoplasmic reticulum stress (ERS) and related signaling pathways were examined by western blotting and IHC. In vitro, human bronchial epithelial cells (HBECs) and A549 cells were treated with transforming growth factor (TGF)β1 with or without Isor, and collagen deposition and the expression levels of EMT‑ and ERS‑related genes or proteins were analyzed by reverse transcription‑quantitative polymerase chain reaction, western blotting, and immunofluorescence. The results demonstrated that Isor inhibited bleomycin‑induced collagen deposition, reduced type I collagen and α‑SMA expression, and alleviated EMT and ERS in vivo. Furthermore, incubation of HBECs and A549 cells with TGFβ1 activated EMT and ERS, and this effect was reversed by Isor. In conclusion, Isor treatment attenuated bleomycin‑induced EMT and pulmonary fibrosis and suppressed bleomycin‑induced ERS and the activation of PERK signaling.

View Figures

View References

1	King TE Jr, Pardo A and Selman M: Idiopathic pulmonary fibrosis. Lancet. 378:1949–1961. 2011. View Article : Google Scholar : PubMed/NCBI
2	Wolters PJ, Collard HR and Jones KD: Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 9:157–179. 2014. View Article : Google Scholar :
3	Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al: An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 183:788–824. 2011. View Article : Google Scholar : PubMed/NCBI
4	Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et al: An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 192:e3-e192015. View Article : Google Scholar
5	Walter N, Collard HR and King TE Jr: Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 3:330–338. 2006. View Article : Google Scholar : PubMed/NCBI
6	Borensztajn K, Crestani B and Kolb M: Idiopathic pulmonary fibrosis: From epithelial injury to biomarkers-insights from the bench side. Respiration. 86:441–452. 2013. View Article : Google Scholar
7	Li T, Yang X, Xin S, Cao Y and Wang N: Paraquat poisoning induced pulmonary epithelial mesenchymal transition through Notch1 pathway. Sci Rep. 7:9242017. View Article : Google Scholar : PubMed/NCBI
8	Wang YC, Liu JS, Tang HK, Nie J, Zhu JX, Wen LL and Guo QL: miR-221 targets HMGA2 to inhibit bleomycin-induced pulmonary fibrosis by regulating TGF-β1/Smad3-induced EMT. Int J Mol Med. 38:1208–1216. 2016. View Article : Google Scholar : PubMed/NCBI
9	Huang M, Wang YP, Zhu LQ, Cai Q, Li H and Yang HF: MAPK pathway mediates epithelial-mesenchymal transition induced by paraquat in alveolar epithelial cells. Environ Toxicol. 31:1407–1414. 2016. View Article : Google Scholar : PubMed/NCBI
10	Takemasa A, Ishii Y and Fukuda T: A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice. Eur Respir J. 40:1475–1482. 2012. View Article : Google Scholar : PubMed/NCBI
11	Back SH, Lee K, Vink E and Kaufman RJ: Cytoplasmic IRE1alpha-mediated XBP1 mRNA splicing in the absence of nuclear processing and endoplasmic reticulum stress. J Biol Chem. 281:18691–18706. 2006. View Article : Google Scholar : PubMed/NCBI
12	Galligan JJ, Smathers RL, Shearn CT, Fritz KS, Backos DS, Jiang H, Franklin CC, Orlicky DJ, Maclean KN and Petersen DR: Oxidative stress and the ER stress response in a murine model for early-stage alcoholic liver disease. J Toxicol. 2012.207594:2012.
13	Baek HA, Kim DS, Park HS, Jang KY, Kang MJ, Lee DG, Moon WS, Chae HJ and Chung MJ: Involvement of endoplasmic reticulum stress in myofibroblastic differentiation of lung fibroblasts. Am J Respir Cell Mol Biol. 46:731–739. 2012. View Article : Google Scholar
14	Tanjore H, Lawson WE and Blackwell TS: Endoplasmic reticulum stress as a pro-fibrotic stimulus. Biochim Biophys Acta. 1832.940–947. 2013.
15	Lawson WE, Cheng DS, Degryse AL, Tanjore H, Polosukhin VV, Xu XC, Newcomb DC, Jones BR, Roldan J, Lane KB, et al: Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci USA. 108:10562–10567. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lawson WE, Crossno PF, Polosukhin VV, Roldan J, Cheng DS, Lane KB, Blackwell TR, Xu C, Markin C, Ware LB, et al: Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: Association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol. 294:L1119–L1126. 2008. View Article : Google Scholar : PubMed/NCBI
17	Chiang CK, Hsu SP, Wu CT, Huang JW, Cheng HT, Chang YW, Hung KY, Wu KD and Liu SH: Endoplasmic reticulum stress implicated in the development of renal fibrosis. Mol Med. 17:1295–1305. 2011. View Article : Google Scholar : PubMed/NCBI
18	Ayala P, Montenegro J, Vivar R, Letelier A, Urroz PA, Copaja M, Pivet D, Humeres C, Troncoso R, Vicencio JM, et al: Attenuation of endoplasmic reticulum stress using the chemical chaperone 4-phenylbutyric acid prevents cardiac fibrosis induced by isoproterenol. Exp Mol Pathol. 92:97–104. 2012. View Article : Google Scholar
19	Spitler KM and Webb RC: Endoplasmic reticulum stress contributes to aortic stiffening via proapoptotic and fibrotic signaling mechanisms. Hypertension. 63:e40-e452014. View Article : Google Scholar
20	Ahn H and Lee GS: Isorhamnetin and hyperoside derived from water dropwort inhibits inflammasome activation. Phytomedicine. 24:77–86. 2017. View Article : Google Scholar : PubMed/NCBI
21	Gao L, Yao R, Liu Y, Wang Z, Huang Z, Du B, Zhang D, Wu L, Xiao L and Zhang Y: Isorhamnetin protects against cardiac hypertrophy through blocking PI3K-AKT pathway. Mol Cell Biochem. 429:167–177. 2017. View Article : Google Scholar : PubMed/NCBI
22	Yang JH, Kim SC, Kim KM, Jang CH, Cho SS, Kim SJ, Ku SK, Cho IJ and Ki SH: Isorhamnetin attenuates liver fibrosis by inhibiting TGF-β/Smad signaling and relieving oxidative stress. Eur J Pharmacol. 783:92–102. 2016. View Article : Google Scholar : PubMed/NCBI
23	Yang B, Li XP, Ni YF, Du HY, Wang R, Li MJ, Wang WC, Li MM, Wang XH, Li L, et al: Protective effect of isorhamnetin on lipopolysaccharide-induced acute lung injury in mice. Inflammation. 39:129–137. 2016. View Article : Google Scholar
24	Knudsen L, Ruppert C and Ochs M: Tissue remodelling in pulmonary fibrosis. Cell Tissue Res. 367:607–626. 2017. View Article : Google Scholar
25	Higashiyama H, Yoshimoto D, Okamoto Y, Kikkawa H, Asano S and Kinoshita M: Receptor-activated Smad localisation in bleomycin-induced pulmonary fibrosis. J Clin Pathol. 60:283–289. 2007. View Article : Google Scholar
26	Zhuang Y, Dai J, Wang Y, Zhang H, Li X, Wang C, Cao M, Liu Y, Ding J, Cai H, et al: MiR-338* targeting smoothened to inhibit pulmonary fibrosis by epithelial-mesenchymal transition. Am J Transl Res. 8:3206–3213. 2016.
27	Rodríguez-Rodríguez C, Torres N, Gutiérrez-Uribe JA, Noriega LG, Torre-Villalvazo I, Leal-Díaz AM, Antunes-Ricardo M, Márquez-Mota C, Ordaz G, Chavez-Santoscoy RA, et al: The effect of isorhamnetin glycosides extracted from Opuntia ficus-indica in a mouse model of diet induced obesity. Food Funct. 6:805–815. 2015. View Article : Google Scholar : PubMed/NCBI
28	Zhao H, Qin HY, Cao LF, Chen YH, Tan ZX, Zhang C and Xu DX: Phenylbutyric acid inhibits epithelial-mesenchymal transition during bleomycin-induced lung fibrosis. Toxicol Lett. 232:213–220. 2015. View Article : Google Scholar
29	Tian R, Zhu Y, Yao J, Meng X, Wang J, Xie H and Wang R: NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis. Exp Cell Res. 357:328–334. 2017. View Article : Google Scholar : PubMed/NCBI
30	Zhou XM, Wang GL, Wang XB 2, Liu L, Zhang Q, Yin Y, Wang QY, Kang J and Hou G: GHK peptide inhibits bleo-mycin-induced pulmonary fibrosis in mice by suppressing TGFbeta1/Smad-mediated epithelial-to-mesenchymal transition. Front Pharmacol. 8:9042017. View Article : Google Scholar
31	Wynn TA and Ramalingam TR: Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med. 18:1028–1040. 2012. View Article : Google Scholar : PubMed/NCBI
32	Uhal BD, Nguyen H, Dang M, Gopallawa I, Jiang J, Dang V, Ono S and Morimoto K: Abrogation of ER stress-induced apoptosis of alveolar epithelial cells by angiotensin 1–7. Am J Physiol Lung Cell Mol Physiol. 305:L33–L41. 2013. View Article : Google Scholar : PubMed/NCBI
33	Winters CJ, Koval O, Murthy S, Allamargot C, Sebag SC, Paschke JD, Jaffer OA, Carter AB and Grumbach IM: CaMKII inhibition in type II pneumocytes protects from bleomycin-induced pulmonary fibrosis by preventing Ca²⁺-dependent apoptosis. Am J Physiol Lung Cell Mol Physiol. 310:L86–L94. 2016. View Article : Google Scholar
34	Wang YC, Dong J, Nie J, Zhu JX, Wang H, Chen Q, Chen JY, Xia JM and Shuai W: Amelioration of bleomycin-induced pulmonary fibrosis by chlorogenic acid through endoplasmic reticulum stress inhibition. Apoptosis. 22:1147–1156. 2017. View Article : Google Scholar : PubMed/NCBI
35	PLOS ONE Staff: Correction: Melatonin inhibits endoplasmic reticulum stress and epithelial-mesenchymal transition during bleomycin-induced pulmonary fibrosis in mice. PLoS One. 10:e1193812015.